FDC share price
NSE: FDCPharma & Healthcare
FDC at a glance
FDC (NSE: FDC) closed at ₹339.20 on 22 Oct 2026, down 0.24% on the day. With a market capitalisation of ₹5,523 Cr, it ranks 751st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.
Its return on equity was 11.7% in FY25. Over the past year the share price has fallen 22.1%. Its 52-week range is ₹312.95 (30 Mar 2026) to ₹473.60 (3 Nov 2025); the last close is 28.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹668 Cr (+3.0% year on year) and net profit ₹132 Cr (+9.2%), on a consolidated basis. Promoters held 69.66% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹5,523 CrRank 751 on NSE
- Price to book
- 2.81×FY25
- EPS (TTM)
- ₹17.98to Q1 FY27
- ROE
- 11.7%FY25
- ROCE
- 15.4%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 12.7%FY25
- Book value / share
- ₹140.11FY25
- Dividend payout
- 30.5%FY25
- 52-week high
- ₹473.603 Nov 2025
- 52-week low
- ₹312.9530 Mar 2026
- 1-year return
- −22.1%
- RSI (14-day)
- 46.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.24% | −3.1% | −6.7% | −17.5% | −22.1% |
FDC quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹514 Cr | ₹464 Cr | ₹492 Cr | ₹648 Cr | ₹473 Cr | ₹465 Cr | ₹585 Cr | ₹668 Cr |
| Revenue YoY | +5.7% | +1.3% | +6.5% | +1.6% | −7.9% | +0.1% | +18.9% | +3.0% |
| Net profit | ₹72 Cr | ₹37 Cr | ₹39 Cr | ₹121 Cr | ₹28 Cr | ₹28 Cr | ₹103 Cr | ₹132 Cr |
| Net profit YoY | +3.2% | −53.2% | −16.4% | +1.9% | −60.6% | −23.6% | +167.4% | +9.2% |
| Net margin | 14.0% | 8.0% | 7.9% | 18.7% | 6.0% | 6.1% | 17.7% | 19.8% |
| EPS | ₹4.43 | ₹2.28 | ₹2.38 | ₹7.45 | ₹1.75 | ₹1.74 | ₹6.35 | ₹8.14 |
FDC financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,344 Cr | ₹1,333 Cr | ₹1,528 Cr | ₹1,784 Cr | ₹1,943 Cr | ₹2,108 Cr |
| Operating profit | ₹321 Cr | ₹390 Cr | ₹289 Cr | ₹258 Cr | ₹396 Cr | ₹357 Cr |
| Net profit | ₹241 Cr | ₹301 Cr | ₹216 Cr | ₹194 Cr | ₹305 Cr | ₹267 Cr |
| EPS (₹) | ₹14.00 | ₹18.00 | ₹13.00 | ₹12.00 | ₹19.00 | ₹16.00 |
| Cash from operations | ₹250 Cr | ₹207 Cr | ₹162 Cr | ₹155 Cr | ₹221 Cr | ₹318 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹1,547 Cr | ₹1,734 Cr | ₹1,957 Cr | ₹1,982 Cr | ₹2,097 Cr | ₹2,281 Cr |
FDC shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 69.66% | 69.66% | 69.66% | 69.66% | 69.66% | 69.66% |
| Foreign institutions | 2.55% | 2.41% | 2.43% | 2.32% | 2.40% | 1.40% |
| Domestic institutions | 6.37% | 7.17% | 6.82% | 6.27% | 6.29% | 6.31% |
| Non-institutions | 21.42% | 20.76% | 21.10% | 21.75% | 21.65% | 22.63% |
FDC vs peers
The listed Pharma & Healthcare companies nearest to FDC by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KOVAIKovai Medical Center & Hospital | ₹5,738.00 | −2.24% | +190.4% | ₹6,279 Cr | 25.7 | — |
| NEPHROPLUSNephrocare Health Services | ₹599.90 | −0.84% | — | ₹6,019 Cr | 74.1 | — |
| SPARCSun Pharma Advanced Research Company | ₹176.82 | −1.22% | +35.4% | ₹5,738 Cr | 3.7 | — |
| SENORESSenores Pharmaceuticals | ₹1,233.30 | +0.35% | +71.0% | ₹5,680 Cr | 46.7 | — |
| INNOVACAPInnova Captab | ₹983.60 | +0.57% | +17.9% | ₹5,629 Cr | 40 | — |
| FDCFDC | ₹339.20 | −0.24% | −22.1% | ₹5,523 Cr | — | — |
| IOLCPIOL Chemicals and Pharmaceuticals | ₹173.27 | −0.76% | +80.5% | ₹5,086 Cr | 36.9 | — |
Ask anything about FDC
Pivot answers on the live chart with evidence you can check, and tests strategies against FDC's own history. Try: “Why has FDC moved over the last three months?” · “Backtest a 50-day moving-average crossover on FDC over five years” · “Compare FDC with KOVAI on margins and valuation”
Frequently asked questions about FDC
What is the share price of FDC today?
FDC (NSE: FDC) last closed at ₹339.20 on 22 Oct 2026. Its 52-week high is ₹473.60 and its 52-week low is ₹312.95.
What is the market cap of FDC?
FDC's market capitalisation is ₹5,523 Cr (₹5,523 Cr) at the 22 Oct 2026 close, ranking 751st among the NSE companies Pivot tracks.
What is the ROE and ROCE of FDC?
Return on equity was 11.7% in FY25 and return on capital employed was 15.4% in FY25 (consolidated figures).
Is FDC a debt-free company?
FDC is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were FDC's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), FDC reported revenue of ₹668 Cr, +3.0% year on year, and net profit of ₹132 Cr, +9.2% year on year.
How has FDC stock performed over the last year?
FDC's share price has fallen 22.1% over the past year, −17.5% over three months and −6.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of FDC?
As of 30 Jun 2026: promoters 69.66%, foreign institutions 1.40%, domestic institutions 6.31%, non-institutions 22.63%.
Who are FDC's competitors?
The listed Pharma & Healthcare companies closest to FDC by market cap are Kovai Medical Center & Hospital, Nephrocare Health Services, Sun Pharma Advanced Research Company, Senores Pharmaceuticals, Innova Captab and IOL Chemicals and Pharmaceuticals.
Is FDC a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out FDC's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FDC against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with F · all NSE stocks · this page as text